AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.30, $0.83 better than the analyst estimate of $0.47. Revenue for the quarter came in at $5.78 billion versus the consensus estimate of $5.45 billion.

GUIDANCE:

AstraZeneca sees FY2018 EPS of $3.30-$3.50, versus the consensus of $1.62.

The PDF could not be displayed inside the page, click here to open.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.